AOC 1001 Earns Orphan Drug Status for DM1 in Europe

AOC 1001 Earns Orphan Drug Status for DM1 in Europe

304473

AOC 1001 Earns Orphan Drug Status for DM1 in Europe

The European Commission (EC) has granted orphan designation to AOC 1001, Avidity Biosciences’ investigational therapy for myotonic dystrophy type 1 (DM1). This designation is given to investigational therapies that have the potential to treat rare, life-threatening, or very serious diseases that affect less than five in 10,000 patients in the European Union. Orphan designation confers certain benefits to companies, including fee reductions, clinical protocol advice, and 10 years of protetion from competition following regulatory approval.…

You must be logged in to read/download the full post.